Ultragenyx Pharmaceutical has recently appointed Dr. Clay Siegal to its Board of Directors. It is a biopharmaceutical firm that specializes in the development of drugs for rare diseases. Dr. Clay Siegal currently assumes the role of Chairman, CEO, and President of the Board of Seattle Genetics. Mr. Fust the former Chief Financial Officer and Vice President of Onyx Pharmaceutical comes in as an independent director of Ultragenyx Pharmaceuticals. Dr. Clay Siegal and Matt were welcomed to the Board of Ultragenyx by Eran Nadav the Board’s Chairman. They bring a broad and diverse experience in the world of cancer research. Their vast knowledge will be used to usher Ultragenyx Pharmaceuticals to its next development phase.
Over time, Ultragenyx Pharmaceuticals has made significant strides in the development of clinical programs. Dr. Siegal hopes to share his in-depth insight about cancer treatment towards the progress of Ultragenyx Pharmaceuticals. His primary focus at the firm would be patients living with rare and ultra-rare diseases. Dr. Clay Siegal feels excited to be part of a company that embarks on innovative, patient-focused approaches to address severe, life-threatening conditions. He looks forward to collaborating with other board members to deliver on this endeavor.
Dr. Clay Sieagal is the current Chairman, President, and CEO of Seattle Genetics, a premier biotech firm that specializes in the commercialization and development of innovative cancer therapies. Before founding Seattle Genetics in 1998, Dr. Clay Siegal worked at the National Institute of Health between 1988 and 1991 as well as the Squibb Pharmaceutical Research Institute in Bristol from 1991 to 1997. Besides his role at Seattle Genetics, Dr. Clay Siegal also serves on the boards of Mirna Therapeutics and Alder Pharmaceuticals. He went to the George Washington University where he earned a Ph.D. in Genetics. He is also a holder of a Zoology degree from the Maryland University.
About Ultragenyx Pharmaceuticals
Ultragenyx Pharmaceuticals is a growing biotech company committed to helping patients affected by rare and ultra-rare diseases. Since its launch in 2010, Ultragenyx Pharmaceuticals has quickly built a diverse portfolio of novel products to help address health conditions with high unmet medical needs.